Phase I clinical trial of the base excision repair inhibitor with fludarabine for patients with advanced hematolog

Oncotarget 8, 79864-79875

DOI: 10.18632/oncotarget.20094

Citation Report

#	Article	IF	Citations
1	Development of Fangjiomics for Systems Elucidation of Synergistic Mechanism Underlying Combination Therapy. Computational and Structural Biotechnology Journal, 2018, 16, 565-572.	1.9	11
2	DNA damage and repair measured by comet assay in cancer patients. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 2019, 843, 95-110.	0.9	43
3	Role of Clinical Pharmacodynamics Studies in the Era of Precision Medicines Against Cancer. , 2019, , $1\text{-}18$.		1
4	Role of Clinical Pharmacodynamics Studies in the Era of Precision Medicines Against Cancer. , 2020, , 343-360.		0
5	Characterization of Recombinant Endonuclease IV from Mycobacterium tuberculosis. Molecular Biology, 2021, 55, 225-233.	0.4	0
7	Base excision repair and its implications to cancer therapy. Essays in Biochemistry, 2020, 64, 831-843.	2.1	56
8	The DNA repair enzyme MUTYH potentiates cytotoxicity of the alkylating agent MNNG by interacting with abasic sites. Journal of Biological Chemistry, 2020, 295, 3692-3707.	1.6	10
9	Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomas. Oncotarget, 2020, 11, 3959-3971.	0.8	8
10	Miscoding and DNA Polymerase Stalling by Methoxyamine-Adducted Abasic Sites. Chemical Research in Toxicology, 2022, 35, 303-314.	1.7	5
11	DNA damage response inhibitionâ€based combination therapies in cancer treatment: Recent advances and future directions. Aging and Cancer, 2022, 3, 44-67.	0.5	2
12	Integrated Pharmacogenetics Analysis of the Three Fangjis Decoctions for Treating Arrhythmias Based on Molecular Network Patterns. Frontiers in Cardiovascular Medicine, 2021, 8, 726694.	1.1	0
13	The Intertwined Role of 8-oxodG and G4 in Transcription Regulation. International Journal of Molecular Sciences, 2023, 24, 2031.	1.8	2
14	Drugs that modulate resistance to antitumor agents. , 2023, , 901-963.		0